LataMed Ai Corp. (LMED) intrinsic value & 10-year financials
LataMed Ai Corp. (LMED) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $0, with an average return on invested capital of 277.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.05
- Market cap
- $1.5M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- 277.5%
- Free cash flow (FY2025)
- —
LMED 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$207.5K | — | — | — | 28.5% |
| FY2024 | $0 | -$3.3M | -$0.11 | — | — | 614.2% |
| FY2023 | $0 | -$1.7M | -$0.02 | — | — | 189.7% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LataMed AI Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LataMed AI Corp. returns on capital have been average, hovering around 12.2% ROIC over the decade.
LataMed AI Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LataMed AI Corp. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.